Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 11/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17002757 | 1.00 | KDM1A (0.56) | KDM1AMAOBMAOAPDE4BMTNR1A | |
| SCHEMBL17003706 | 0.91 | KDM1A (0.56) | KDM1AMAOBMAOAPDE4BMTNR1A | |
| SCHEMBL17003707 | 0.91 | KDM1A (0.56) | KDM1AMAOBMAOAPDE4BMTNR1A | |
| SCHEMBL17002684 | 0.86 | KDM1A (0.56) | KDM1AMAOBMAOAPDE4B | |
| SCHEMBL17002687 | 0.86 | KDM1A (0.56) | KDM1AMAOBMAOAPDE4B | |
| SCHEMBL30394598 | 0.81 | PDE4B (0.49) | KDM1APDE4B | |
| SCHEMBL17002845 | 0.81 | PDE4B (0.49) | KDM1APDE4B | |
| SCHEMBL17002842 | 0.81 | PDE4B (0.49) | KDM1APDE4B | |
| SCHEMBL24890658 | 0.80 | KDM1A (0.67) | KDM1AMAOBMAOAPDE4BKDM4E | |
| SCHEMBL17002866 | 0.80 | KDM1A (0.67) | KDM1AMAOBMAOAPDE4BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2907802-B1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-9751885-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| US-20150266881-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| EP-2907802-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2015-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266881-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | BHMT, HNMT, KDM1A | KDM1A 3/4885MAOB 27/4885MAOA 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.